Figure 4.
Figure 4. Lysis of primary AML blasts and malignant B-CLL cells endogenously expressing OFA-iLRP. HLA-A2+/OFA-iLRP+ leukemic blasts (A; AML 1, 3, 5, 6), HLA-A2-/OFA-iLRP+ blasts (B; AML 2, 4), HLA-A2+/OFA-iLRP+ B-CLL cells (C; CLL1, CLL3), and HLA-A2-/OFA-iLRP+ B-CLL cells (D; CLL2, CLL4) were used as targets in a 4-hour 51Chromium release assay. One representative experiment is shown.

Lysis of primary AML blasts and malignant B-CLL cells endogenouslyexpressing OFA-iLRP. HLA-A2+/OFA-iLRP+ leukemic blasts (A; AML 1, 3, 5, 6), HLA-A2-/OFA-iLRP+ blasts (B; AML 2, 4), HLA-A2+/OFA-iLRP+ B-CLL cells (C; CLL1, CLL3), and HLA-A2-/OFA-iLRP+ B-CLL cells (D; CLL2, CLL4) were used as targets in a 4-hour 51Chromium release assay. One representative experiment is shown.

Close Modal

or Create an Account

Close Modal
Close Modal